NYSE American
Every company in the roster listed on NYSE American.
Every company in the roster listed on NYSE American.
4 of 4 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Protalix BioTherapeutics, Inc.PLX · NYSE American | 2 assets: 1 approved, 1 Ph 2 | PRX-115Phase 2 · Severe Refractory Gout | Oct 2027pegunigalsidase alfa · Phase 2/3 | $255M | $22MSep 2026 | Cash-flow positive | $22M |
Annovis Bio (NYSE American: ANVS)ANVS · NYSE American | 1 asset: 1 Ph 3 | BuntanetapPhase 3 · Alzheimer's DiseasePartial signal | Dec 2027Buntanetap · Phase 3 | $36M | $2.8MSep 2026 | Ended Oct 2026 | $53M |
Serina TherapeuticsSER · NYSE American | 1 asset: 1 Ph 1 | SER-252 (PEOZ-apomorphine)Phase 1 · Parkinson's Disease | 31 Jan 2027SER-252 (PEOZ-apomorphine) · Phase 1 | $34M | $19MSep 2026 | ~3.4 qtrs | $15M |
Pelthos Therapeutics Inc.PTHS · NYSE American | 1 asset: 1 approved | Approved assets only | None on record | $27M | $18MSep 2026 | ~2.2 qtrs | $2.2M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.